The global hematologic cancers testing market is exhibiting significant increase, propelled by a rising occurrence of myeloma and other related diseases. Researchers estimate the existing market scope to be substantial, with projections indicating a steady compound annual increase rate (CAGR) over the projected period. Key drivers shaping the lands